atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Medway NHS Foundation Trust, one of the largest and most innovative NHS trusts in the South-East of England, has taken a bold step forward in its virtual care journey by transitioning to a new digital platform – part of its…
Chancellor Rachel Reeves announced that the government is investing up to £10bn to bring the NHS “into the digital age” as part of the latest spending review.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us